|
|
Vaccine Detail
|
ALVAC-hB7.1 |
| Vaccine Information |
- Vaccine Name: ALVAC-hB7.1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007246
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CTLA4
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: A recombinant canarypox virus is used to intratumorally deliver the immune costimulatory molecule B7.1 (Triozzi et al., 2005)
- Description: A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient. (NCI04) (NCIT_C2485).
This vaccine has been used in melanoma patients. NCT00003556
|
| Host Response |
|
|
| References |
NCIT_C2485: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2485]
Triozzi et al., 2005: Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11(11); 4168-4175. [PubMed: 15930353].
|
|
